In silico high-throughput screening system for INMT activators in prostate cancer therapy
Frontiers in Pharmacology · 23.07.2026 · 17
DOI: 10.3389/fphar.2026.1852736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.07.2026. Verfasst von Haoyuan Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, First Hospital of China Medical University, Shenyang, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Prostate cancer (PCa) is one of the leading causes of cancer-related mortality in men, with castration-resistant prostate cancer (CRPC) posing significant therapeutic challenges due to drug resistance mediated by the androgen receptor (AR) signaling pathway. Indolethylamine-N-methyltransferase (INMT), a tumor-suppressive enzyme downregulated in CRPC, regulates pathways associated with apoptosis and proliferation. Leveraging a structure-based drug design strategy, this study aimed to identify novel INMT agonists for CRPC therapy. Virtual screening of the ChemDiv compound library (guided by the INMT crystal structure, PDB ID: 2A14), combined with molecular docking, MM/GBSA binding energy calculations, and molecular dynamics simulations, identified five candidate compounds. Among these, DMPP-4M stably bound to an allosteric site adjacent to the catalytic domain of INMT via hydrogen bonds, π-cation interactions, and hydrophobic forces. In vitro experiments demonstrated that DMPP-4M dose-dependently upregulated INMT expression, inhibited proliferation, and induced apoptosis in CRPC cell models (PC-3, 22RV1). The mechanism involved activation of the pro-apoptotic protein BAX, suppression of the anti-apoptotic protein Bcl-2, and upregulation of cleaved caspase-3 and PARP. Further mechanistic studies revealed that DMPP-4M-mediated INMT activation suppressed the activity of the TGF-β/Smad and Wnt/β-catenin signaling pathways. These findings suggest that DMPP-4M represents a promising INMT-targeted therapeutic agent, offering an AR-independent strategy for CRPC treatment. Subsequent structural optimization and in vivo experimental validation are required to advance its clinical translation potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, First Hospital of China Medical University, Shenyang, China.
- Institute of Urology, China Medical University, Shenyang, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zheng, H., Cao, S., Kong, Z., Xin, P., Bi, J., & Wang, J. (2026). In silico high-throughput screening system for INMT activators in prostate cancer therapy. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1852736
Vancouver
Zheng H, Cao S, Kong Z, Xin P, Bi J, Wang J. In silico high-throughput screening system for INMT activators in prostate cancer therapy. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1852736
BibTeX
@article{Zheng2026,
author = {Zheng, Haoyuan and Cao, Shilong and Kong, Zhuoling and Xin, Peng and Bi, Jianbin and Wang, Jianfeng},
title = {In silico high-throughput screening system for INMT activators in prostate cancer therapy},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1852736}
}
EUVIMED